Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 107

1.

Targeted alpha particle immunotherapy for myeloid leukemia.

Jurcic JG, Larson SM, Sgouros G, McDevitt MR, Finn RD, Divgi CR, Ballangrud AM, Hamacher KA, Ma D, Humm JL, Brechbiel MW, Molinet R, Scheinberg DA.

Blood. 2002 Aug 15;100(4):1233-9.

PMID:
12149203
[PubMed - indexed for MEDLINE]
Free Article
2.

Sequential cytarabine and alpha-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemia.

Rosenblat TL, McDevitt MR, Mulford DA, Pandit-Taskar N, Divgi CR, Panageas KS, Heaney ML, Chanel S, Morgenstern A, Sgouros G, Larson SM, Scheinberg DA, Jurcic JG.

Clin Cancer Res. 2010 Nov 1;16(21):5303-11. doi: 10.1158/1078-0432.CCR-10-0382. Epub 2010 Sep 21.

PMID:
20858843
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

A phase I trial of humanized monoclonal antibody HuM195 (anti-CD33) with low-dose interleukin 2 in acute myelogenous leukemia.

Kossman SE, Scheinberg DA, Jurcic JG, Jimenez J, Caron PC.

Clin Cancer Res. 1999 Oct;5(10):2748-55.

PMID:
10537338
[PubMed - indexed for MEDLINE]
Free Article
4.

Radiolabeled anti-CD33 monoclonal antibody M195 for myeloid leukemias.

Jurcic JG, Caron PC, Nikula TK, Papadopoulos EB, Finn RD, Gansow OA, Miller WH Jr, Geerlings MW, Warrell RP Jr, Larson SM, et al.

Cancer Res. 1995 Dec 1;55(23 Suppl):5908s-5910s.

PMID:
7493368
[PubMed - indexed for MEDLINE]
Free Article
5.

Supersaturating infusional humanized anti-CD33 monoclonal antibody HuM195 in myelogenous leukemia.

Caron PC, Dumont L, Scheinberg DA.

Clin Cancer Res. 1998 Jun;4(6):1421-8.

PMID:
9626458
[PubMed - indexed for MEDLINE]
Free Article
6.

Antibody therapy for residual disease in acute myelogenous leukemia.

Jurcic JG.

Crit Rev Oncol Hematol. 2001 Apr;38(1):37-45. Review.

PMID:
11255080
[PubMed - indexed for MEDLINE]
7.

Pharmacokinetics and dosimetry of an alpha-particle emitter labeled antibody: 213Bi-HuM195 (anti-CD33) in patients with leukemia.

Sgouros G, Ballangrud AM, Jurcic JG, McDevitt MR, Humm JL, Erdi YE, Mehta BM, Finn RD, Larson SM, Scheinberg DA.

J Nucl Med. 1999 Nov;40(11):1935-46.

PMID:
10565792
[PubMed - indexed for MEDLINE]
Free Article
8.

Antibody therapy in acute myeloid leukemia: current status and future directions.

Burke JM, Jurcic JG.

Clin Lymphoma. 2002 Mar;2 Suppl 1:S12-8. Review.

PMID:
11970765
[PubMed - indexed for MEDLINE]
9.

Immunotherapy for acute myeloid leukemia.

Jurcic JG.

Curr Oncol Rep. 2005 Sep;7(5):339-46. Review.

PMID:
16091194
[PubMed - indexed for MEDLINE]
10.

Bone marrow purging studies in acute myelogenous leukemia using the recombinant anti-CD33 immunotoxin HuM195/rGel.

Duzkale H, Pagliaro LC, Rosenblum MG, Varan A, Liu B, Reuben J, Wierda WG, Korbling M, McMannis JD, Glassman AB, Scheinberg DA, Freireich EJ.

Biol Blood Marrow Transplant. 2003 Jun;9(6):364-72.

PMID:
12813444
[PubMed - indexed for MEDLINE]
11.

Alpha-emitting bismuth cyclohexylbenzyl DTPA constructs of recombinant humanized anti-CD33 antibodies: pharmacokinetics, bioactivity, toxicity and chemistry.

Nikula TK, McDevitt MR, Finn RD, Wu C, Kozak RW, Garmestani K, Brechbiel MW, Curcio MJ, Pippin CG, Tiffany-Jones L, Geerlings MW Sr, Apostolidis C, Molinet R, Geerlings MW Jr, Gansow OA, Scheinberg DA.

J Nucl Med. 1999 Jan;40(1):166-76.

PMID:
9935073
[PubMed - indexed for MEDLINE]
Free Article
12.

Antibody therapy of acute myelogenous leukemia.

Jurcic JG.

Cancer Biother Radiopharm. 2000 Aug;15(4):319-26. Review.

PMID:
11041016
[PubMed - indexed for MEDLINE]
13.

Cytoreduction with iodine-131-anti-CD33 antibodies before bone marrow transplantation for advanced myeloid leukemias.

Burke JM, Caron PC, Papadopoulos EB, Divgi CR, Sgouros G, Panageas KS, Finn RD, Larson SM, O'Reilly RJ, Scheinberg DA, Jurcic JG.

Bone Marrow Transplant. 2003 Sep;32(6):549-56.

PMID:
12953125
[PubMed - indexed for MEDLINE]
14.

Nuclear localizing sequences promote nuclear translocation and enhance the radiotoxicity of the anti-CD33 monoclonal antibody HuM195 labeled with 111In in human myeloid leukemia cells.

Chen P, Wang J, Hope K, Jin L, Dick J, Cameron R, Brandwein J, Minden M, Reilly RM.

J Nucl Med. 2006 May;47(5):827-36.

PMID:
16644753
[PubMed - indexed for MEDLINE]
Free Article
15.

Antibody-targeted therapy for myeloid leukemia.

Appelbaum FR.

Semin Hematol. 1999 Oct;36(4 Suppl 6):2-8. Review.

PMID:
10530710
[PubMed - indexed for MEDLINE]
16.

Drug-resistant AML cells and primary AML specimens are killed by 111In-anti-CD33 monoclonal antibodies modified with nuclear localizing peptide sequences.

Kersemans V, Cornelissen B, Minden MD, Brandwein J, Reilly RM.

J Nucl Med. 2008 Sep;49(9):1546-54. doi: 10.2967/jnumed.107.047399. Epub 2008 Aug 14.

PMID:
18703602
[PubMed - indexed for MEDLINE]
Free Article
17.

Antileukemic activity of recombinant humanized M195-gelonin immunotoxin in nude mice.

Xu Y, Xu Q, Rosenblum MG, Scheinberg DA.

Leukemia. 1996 Feb;10(2):321-6.

PMID:
8637241
[PubMed - indexed for MEDLINE]
18.

Murine and humanized constructs of monoclonal antibody M195 (anti-CD33) for the therapy of acute myelogenous leukemia.

Caron PC, Schwartz MA, Co MS, Queen C, Finn RD, Graham MC, Divgi CR, Larson SM, Scheinberg DA.

Cancer. 1994 Feb 1;73(3 Suppl):1049-56.

PMID:
8306247
[PubMed - indexed for MEDLINE]
19.

Humanized M195 monoclonal antibody conjugated to recombinant gelonin: an anti-CD33 immunotoxin with antileukemic activity.

Pagliaro LC, Liu B, Munker R, Andreeff M, Freireich EJ, Scheinberg DA, Rosenblum MG.

Clin Cancer Res. 1998 Aug;4(8):1971-6.

PMID:
9717827
[PubMed - indexed for MEDLINE]
Free Article
20.

Preparation of alpha-emitting 213Bi-labeled antibody constructs for clinical use.

McDevitt MR, Finn RD, Ma D, Larson SM, Scheinberg DA.

J Nucl Med. 1999 Oct;40(10):1722-7.

PMID:
10520715
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk